Accueil / Tag Archives: Clinical Trials

Tag Archives: Clinical Trials

Forbius’ AVID100, a Novel Anti-EGFR ADC, Reports Positive Phase 1 Data at AACR: Exceptionally High RP2D Established, Phase 2 in SCCHN and sqNSCLC Ongoing

Friday, March 29th 2019 at 7:44pm UTC AVID100 is the only clinical-stage anti-EGFR ADC that targets both wild-type and mutant forms of EGFR with limited off-tumor toxicity due to novel mechanism of action Phase 1 confirmed that AVID100 was well-tolerated and established a recommended phase 2 dose (RP2D) of 220 …

Plus »

Celularity Announces Results of Phase 1 Studies of PNK-007, an Allogeneic, Off-the-Shelf, Placental-Derived Cell Therapy, at AACR Annual Meeting 2019

Friday, March 29th 2019 at 7:15pm UTC First-ever Results to be Presented from Multiple Studies Evaluating Company’s PNK Allogeneic Cell Therapy in Patients with Acute Myeloid Leukemia and Multiple Myeloma WARREN, N.J.–(BUSINESS WIRE)– Celularity, Inc. (“Celularity” or the “Company”), a clinical-stage cell therapeutics company developing allogeneic cellular therapies harnessed from …

Plus »

Northern Biologics Reports Initial Phase I Data for MSC-1 at AACR

Friday, March 29th 2019 at 7:01pm UTC TORONTO–(BUSINESS WIRE)– Northern Biologics Inc., a company focused on developing first-in-class immuno-oncology products, today announced the presentation of initial results from the Phase I trial of their lead antibody, MSC-1, at the American Association for Cancer Research meeting in Atlanta, Georgia. Session Title: …

Plus »

Preliminary Data from Phase 1 Study Evaluating ADXS-NEO Suggest Rapid Immunogenicity and Clinical Activity

Friday, March 29th 2019 at 7:00pm UTC Data to be Presented at AACR Annual Meeting PRINCETON, N.J.–(BUSINESS WIRE)– Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces the presentation of ADXS-NEO data in a poster discussion entitled “Safety and Immunogenicity of …

Plus »

CEL-SCI Reports Recent Data Review by the Independent Data Monitoring Committee for Its Pivotal Phase 3 Head and Neck Cancer Study

Friday, March 29th 2019 at 1:00pm UTC VIENNA, Va.–(BUSINESS WIRE)– CEL-SCI Corporation (NYSE American: CVM) announced today that the Independent Data Monitoring Committee (IDMC) for the Company’s pivotal Phase 3 head and neck cancer study of its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) has completed its recent review of the …

Plus »

Celgene Receives CHMP Positive Opinions for Both REVLIMID® (lenalidomide) and IMNOVID® (pomalidomide)-Based Triplet Combination Regimens for Patients with Multiple Myeloma

Friday, March 29th 2019 at 12:12pm UTC The CHMP adopted two positive opinions recommending European Commission approval of: REVLIMID in combination with bortezomib and dexamethasone (RVd) in adult patients with previously untreated multiple myeloma who are not eligible for transplant IMNOVID in combination with bortezomib and dexamethasone (PVd), for adult …

Plus »

Seattle Genetics Completes Enrollment in Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer

Friday, March 29th 2019 at 12:00pm UTC -Phase 2 innovaTV 204 Trial Designed to Support Potential Accelerated Approval Pathway in U.S.- BOTHELL, Wash.–(BUSINESS WIRE)– Seattle Genetics, Inc. (Nasdaq:SGEN) today announced completion of enrollment in the potentially pivotal innovaTV 204 phase 2 clinical trial evaluating the efficacy, safety and tolerability of …

Plus »

Boehringer Ingelheim Enhances Oncology R&D with Novel MacroDel Delivery Technology Via Acquisition of ICD Therapeutics

Friday, March 29th 2019 at 12:00pm UTC New molecular platform to access intracellular targets across a broad range of tumor cell types Opens up new range of therapeutic opportunities for difficult-to-treat cancers INGELHEIM, Germany & BERLIN–(BUSINESS WIRE)– Boehringer Ingelheim today announced that it acquired ICD Therapeutics. The acquisition includes rights …

Plus »

Bicycle Therapeutics to Present Preclinical Data on EphA2 and Nectin-4 Bicycle Toxin Conjugate Programs, as well as a CD137 Immune Oncology Program, at the American Association for Cancer Research Annual Meeting

Friday, March 29th 2019 at 12:00pm UTC CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)– Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle™) product platform, announced today that Bicycle scientists have been selected to present two oral presentations at the American Association for …

Plus »

Datos publicados en The Lancet demuestran que CT-P13 no es inferior al Infliximab de referencia para el tratamiento de la enfermedad inflamatoria intestinal.

Friday, March 29th 2019 at 11:47am UTC El primer estudio de su especie, demuestra que CT-P13 es comparable en eficacia, seguridad y tolerabilidad al Infliximab de referencia en pacientes con enfermedad de Crohn activa, validando los datos de aprobación extrapolados en esta indicación LONDRES–(BUSINESS WIRE)– Celltrion Healthcare ha anunciado hoy …

Plus »
>
Macbook Pro
* Intel Core i7 (3.8GHz, 6MB cache)
* Retina Display (2880 x 1880 px)
* NVIDIA GeForce GT 750M (Iris)
* 802.11ac Wi-Fi and Bluetooth 4.0
* Thunderbolt 2 (up to 20Gb/s)
* Faster All-Flash Storage (X1)
* Long Lasting Battery (9 hours)
BIENVENUE CHEZ BIOTECH FINANCES
Vous appréciez nos informations ?
Recevez nos alertes, nos dernières actualités, suivez-nous, enregistrez-vous gratuitement, rejoignez notre communauté. Merci à vous !
ARE YOU READY? GET IT NOW!
Increase more than 500% of Email Subscribers!
Your Information will never be shared with any third party.
DÉCOUVREZ LA SOLUTION STRATA !
PGlmcmFtZSB3aWR0aD0iMTAwJSIgaGVpZ2h0PSIxMDAlIiBzcmM9Imh0dHBzOi8vd3d3LmJpb3RlY2gtZmluYW5jZXMuY29tL3dwLWNvbnRlbnQvdXBsb2Fkcy8yMDE1LzA3L1NhdHJhLTIubXA0IiBmcmFtZWJvcmRlcj0iMCIgYWxsb3dmdWxsc2NyZWVuPjwvaWZyYW1lPg==
Retrouvez nous sur http://stratahealth.com/fr/
Un ensemble de solutions performantes
pour assurer le continuum de vos données.
Biotech Finances
SUIVEZ-NOUS, ENREGISTREZ-VOUS !
PGlmcmFtZSB3aWR0aD0iMTAwJSIgaGVpZ2h0PSIxMDAlIiBzcmM9Imh0dHA6Ly93d3cueW91dHViZS5jb20vZW1iZWQvajhsU2NITzJtTTAiIGZyYW1lYm9yZGVyPSIwIiBhbGxvd2Z1bGxzY3JlZW4+PC9pZnJhbWU+
All rights reserved © Company Name, 2014
Concours Genopole Young Biotech Award
* 100 000 € pour la meilleure Biotech
* Réservé aux biotechs hors santé
* 6 mois d'hébergement gratuit
* Un accompagnement personnalisé
* Etude de marché offerte
* Expertise du projet par EY
* Et nombre d'autres avantages...
S'inscrire au 15H BIOTECH EXPRESS
Chaque jour à 15H recevez gratuitement les news des biotechs, des medtechs,et des fonds spécialisés. Levées ; partenariats ; nominations ; fusacq ; closing ; milestone...
2019 (C) All rights reserved.

En cochant cette case, j’accepte la Politique de confidentialité de ce site et de recevoir des informations de notre part.

S'inscrire au 15H BIOTECH EXPRESS
Chaque jour à 15H recevez gratuitement les news des biotechs, des medtechs,et des fonds spécialisés. Levées ; partenariats ; nominations ; fusacq ; closing ; milestone...
2019 (C) All rights reserved.

En cochant cette case, j’accepte la Politique de confidentialité de ce site et de recevoir des informations de notre part.